Investigational drug · Phase 2
Apomivir
Also called: FE-L-APO, drug substance
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza.
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Apomivir"
First trial start
2026
May 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Apomivir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Apomivir" as an intervention, largest first.
- Study to Investigate the Efficacy and Safety of Apomivir®Pivotal-lookingNot yet recruiting
Far East Bio-Tec Co., LtdIndustry
NCT01677689 · 196 participants (planned) · Start May 31, 2026 · Primary completion May 31, 2027
Drug: Apomivir®; Placebo · For: Influenza
Sites: Taichung, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Validated LC-MS/MS method for ultra-trace determination of N-nitroso-desmethyl sumatriptan in sumatriptan succinate injection.
Degekar G S, Patra N · J Pharm Biomed Anal 2027
- An analytical quality by design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product.
Zhang Y, Sacré PY, Streel B, et al. · J Pharm Biomed Anal 2027
- Decoding thermal instability in peptide therapeutics links microheterogeneity to bioactivity loss.
Zhu S, Ge Y, Huang H, et al. · J Pharm Biomed Anal 2026
- Stress-Induced Degradation Profiling of Evogliptin by Stability-Indicating Reversed-Phase High-Performance Liquid Chromatography and Liquid Chromatography-Mass Spectrometry.
Saraf B, Mehta P, Somani R · Biomed Chromatogr 2026
- From prediction to performance: In silico-supported formulation of amorphous solid dispersions for PROTAC NX-2127.
Stakemeier A, Mild L, Sievers J, et al. · Int J Pharm X 2026
- In vitro transcription for RNA vaccines and therapeutics: a quality-by-design perspective on manufacturability.
Nair A, Kis Z · Biotechnol Adv 2026
Also in development for Influenza
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- BRC-201TG-1000, Pixavir MarboxilPhase 31 trial
Boryung Biopharma Co., Ltd. · Influenza
- mRNA-1018-H5Phase 31 trial
Moderna · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- OVX836Phase 21 trial
Osivax · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.